The US National Institutes of Health has made a deal with Pfizer, AstraZeneca, and Eli Lilly to share "abandoned experimental drugs" with academic researchers, reports ScienceInsider's Jocelyn Kaiser. The hope, Kaiser says, is that researchers will be able to find new uses for the drugs. The companies will grant access to two dozen compounds that have passed safety studies, but were deemed ineffective for a specific purpose.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.